Matsuo Toshihiko, Tanaka Takehiro, Shien Tadahiko, Muraoka Atsushi, Doihara Hiroyoshi
Division of Healthcare Science, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama, JPN.
Department of Ophthalmology, Okayama University Hospital, Okayama, JPN.
Cureus. 2025 May 4;17(5):e83484. doi: 10.7759/cureus.83484. eCollection 2025 May.
Breast cancer causes choroidal metastases on rare occasions. This study presented the eye manifestations of choroidal metastases from breast cancer and their response to treatments in detail as well as their pathological correlation in five patients. The patients' age at the diagnosis of breast cancer ranged from 24 to 69 years (median: 37 years). The time from the diagnosis of breast cancer to the detection of metastases was concurrent in one patient, two years later in three patients, and six years later in the other patient. The time from the detection of systemic metastases to the detection of choroidal metastases was the same in one patient, while it ranged from one to seven years later in four patients. Choroidal metastases were in the unilateral eye of four patients, whereas they were in both eyes of one patient. Choroidal metastases manifested as one or a few nodular or flat choroidal lesions with serous retinal detachment. As for the treatment of choroidal metastases, enucleation of the right eye was chosen based on the patient's wish as well as the family's wish in the earliest patient when cancer notification was not the norm in Japan. In the other four patients, whole-eye radiation was performed to reduce the choroidal metastatic lesions. As regards the prognosis, which was available in four patients, three patients died within one year from the diagnosis of choroidal metastases, while one patient died one year and eight months later. Regarding the pathology of breast cancer, which was available in four patients, immunostaining of the preserved enucleated eye in the earliest patient revealed that breast cancer cells in the choroidal metastatic lesion were positive for estrogen receptor and negative for progesterone receptor and human epidermal growth factor receptor 2 (HER2). Invasive ductal carcinoma in two patients was positive for estrogen receptor and negative for HER2, while invasive ductal carcinoma in the other patient was triple-negative for estrogen receptor, progesterone receptor, and HER2 with a high Ki-67 index. In conclusion, the prognosis for life was poor in patients with breast cancer who developed choroidal metastases. Choroidal metastatic lesions showed a response to whole-eye radiation to improve the quality of vision at the end of life. Vision-related symptoms should be monitored in the course of chemotherapy for systemic metastases.
乳腺癌极少会引发脉络膜转移。本研究详细呈现了5例乳腺癌脉络膜转移患者的眼部表现、治疗反应以及病理相关性。乳腺癌确诊时患者年龄在24至69岁之间(中位数:37岁)。从乳腺癌确诊到发现转移的时间,1例患者为同时发生,3例患者为两年后,另1例患者为六年后。从发现全身转移到发现脉络膜转移的时间,1例患者相同,4例患者则在1至7年后。脉络膜转移发生在4例患者的单眼,1例患者的双眼。脉络膜转移表现为一个或几个结节状或扁平状脉络膜病变伴浆液性视网膜脱离。关于脉络膜转移的治疗,在日本癌症告知尚不规范的最早一例患者中,根据患者及其家属意愿选择了右眼摘除术。在其他4例患者中,进行了全眼放疗以减少脉络膜转移病灶。关于4例患者的预后情况,3例患者在脉络膜转移确诊后一年内死亡,1例患者在一年零八个月后死亡。关于4例患者的乳腺癌病理情况,最早一例患者保存的摘除眼球免疫染色显示,脉络膜转移病灶中的乳腺癌细胞雌激素受体呈阳性,孕激素受体和人表皮生长因子受体2(HER2)呈阴性。2例患者的浸润性导管癌雌激素受体呈阳性,HER2呈阴性,而另1例患者的浸润性导管癌雌激素受体、孕激素受体和HER2均为三阴性,Ki-67指数较高。总之,发生脉络膜转移的乳腺癌患者生存预后较差。脉络膜转移病灶对全眼放疗有反应,可在生命末期改善视力。在全身转移化疗过程中应监测视力相关症状。